A Danish population-based analysis of 105 mantle cell lymphoma patients: incidences, clinical features, response, survival and prognostic factors

Eur J Cancer. 2002 Feb;38(3):401-8. doi: 10.1016/s0959-8049(01)00366-5.

Abstract

This study presents the first large clinical analysis of 105 unselected mantle cell lymphoma (MCL) patients diagnosed from 1992 to 2000 in a well-defined Danish population. The annual incidences were 0.7/100000 for men and 0.2/100000 for women, with no significant change during the study period. Of 97 evaluable cases, 43% achieved a complete response (CR) after initial therapy. The median disease-free (DFS) and overall survival (OS) rates were 15 and 30 months, respectively. In multivariate analysis, splenomegaly (P=0.002), anaemia (P=0.0001) and age (P=0.002), but not the international prognostic index (IPI) and the Ann Arbor staging system, had an independent impact on survival. Moreover, in a sub-analysis of 45 younger MCL patients (<65 years), a trend towards an OS plateau of 58% was observed in cases without splenomegaly and anaemia (n=29). Thus, in contrast to previously suggested prognostic factors, these variables may prove useful for clinical decisions in a significant subset of MCL patients.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Age Distribution
  • Aged
  • Aged, 80 and over
  • Antineoplastic Combined Chemotherapy Protocols / therapeutic use
  • Denmark / epidemiology
  • Disease-Free Survival
  • Female
  • Humans
  • Immunohistochemistry / methods
  • Immunophenotyping / methods
  • Incidence
  • Lymphoma, Mantle-Cell / drug therapy
  • Lymphoma, Mantle-Cell / mortality*
  • Lymphoma, Mantle-Cell / pathology
  • Male
  • Multivariate Analysis
  • Neoplasm Staging / methods
  • Population Surveillance
  • Prognosis